Thomas Jefferson University
jefferson.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
383
Active
79
Phase 3
22
Total enrollment
47,231
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ferumoxytol | — | — | — | — | — | 2 | |
| Ferrous Sulfate | — | — | — | — | — | 2 | |
| ketamine | — | — | — | — | 2 | ||
| Acetaminophen | — | — | — | — | — | 1 | |
| NSAID | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 1 | |
| Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h | — | — | — | — | — | 1 | |
| SHAPE measurement | — | — | — | — | 2 | ||
| Perflutren lipid microsphere | — | — | — | — | 2 | ||
| Perflutren Lipid Microspheres | — | — | — | — | — | 1 | |
| Tenofovir Alafenamide | — | — | — | — | 2 | ||
| Tebentafusp-Tebn | — | — | — | — | — | 2 | |
| Tacrolimus | — | — | — | 3 | |||
| Cyclophosphamide | — | — | — | — | — | 2 | |
| Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE | — | — | — | — | — | 1 | |
| Ultrasound-triggered microbubble destruction with antibiotics | — | — | — | — | — | 1 | |
| GM-CSF | — | — | — | — | — | 1 | |
| BCNU | — | — | — | — | — | 1 | |
| Daily aspirin | — | — | — | — | — | 1 | |
| Split dose aspirin | — | — | — | — | — | 1 | |
| Plerixafor | — | — | — | — | — | 1 | |
| Gcsf | — | — | — | — | — | 1 | |
| Perfluten | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| IDO1 Inhibitor BMS-986205 | — | — | — | — | — | 1 | |
| Pacritinib | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| 50% Dextrose Pleurodesis | — | — | — | — | — | 1 | |
| Carmustine | — | — | — | — | — | 1 | |
| Ethiodized Oil | — | — | — | — | — | 1 | |
| [F-18] Fluorodopa Positron Emission Tomography | — | — | — | — | — | 1 | |
| Extended-release Onapristone | — | — | — | — | — | 1 | |
| Anastrozole | — | — | — | — | — | 1 | |
| SHAPE measurement using the ultrasound contrast agent Sonazoid | — | — | — | — | — | 1 | |
| SHAPE measurement using the ultrasound contrast agent Lumason | — | — | — | — | — | 1 | |
| Definity | — | — | 4 | ||||
| Pembrolizumab | — | — | — | — | 2 |
17 more active programs hidden
Next readouts
- 2017-07-10
- 2020-08-15
- 2024-05-16
- 2024-08-01
- 2025-04-11
- 2025-05-26
- 2025-07
- 2025-08-31
- 2025-12-31
- 2025-12-31
Top conditions
- Migraine14
- Heart Failure8
- Malignant Solid Neoplasm8
- Pain7
- Breast Cancer6
- Prostate Carcinoma5
- Hematopoietic and Lymphoid Cell Neoplasm5
- Preterm Birth5
Frequently asked questions about Thomas Jefferson University
- How many clinical trials does Thomas Jefferson University have on ClinicalTrials.gov?
- Thomas Jefferson University is listed as the lead sponsor on 383 clinical trials in ClinicalTrials.gov, 79 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Thomas Jefferson University's trials are in Phase 3?
- 22 of Thomas Jefferson University's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does Thomas Jefferson University focus on?
- Thomas Jefferson University's most-studied conditions on ClinicalTrials.gov are Migraine, Heart Failure, Malignant Solid Neoplasm, Pain, Breast Cancer.
- When are Thomas Jefferson University's next clinical trial readouts?
- Thomas Jefferson University has 10 upcoming primary-completion readouts tracked here; the soonest is “Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer”, expected around 2017-07-10.